Buy Eliquis (Apixaban)

Inside, regardless of food intake.

 

In case of missed intake, the drug should be taken as soon as possible and then continue to take it 2 times a day according to the original scheme.

 

For patients who cannot swallow the whole tablet, Eliquis® can be crushed and diluted in water or 5% aqueous dextrose (5DB) or apple juice or mixed with apple puree and given to the patient for immediate ingestion.

 

The medicinal substance in the shredded tablets of Eliquis® maintains stability in water, 5DB, apple juice and apple puree up to 4 hours.

 

 

1. Patients after planned hip or knee joint endoprosthetics: 
1 table 2.5 mg 2 times a day (first in 12-24 h after surgical intervention).

 

For patients who have undergone hip arthroplasty, the recommended therapy duration is 32-38 days, for knee joints - 10-14 days.

 

 

2. Patients with atrial fibrillation: 
1 table 5 mg twice a day.

 

For patients with atrial fibrillation the preparation dose is reduced to 2.5 mg (tablet 2.5 mg) twice a day:

 

- In the presence of a combination of two or more of the following characteristics - age 80 years and older, body weight 60 kg or less or creatinine plasma concentration ≥1.5 mg/dL (133 µmol/l).

 

 

3. DVT treatment, EP (pulmonary artery thromboembolism): 
10 mg 2 times a day for 7 days, then - 5 mg 2 times a day.

 

The duration of treatment is determined individually, taking into account the ratio of expected benefit to the risk of clinically significant bleeding. The decision on the duration of treatment should be based on an assessment of the presence and reversibility of factors predisposing to recurrence (i.e., previous surgery, trauma, period of immobilization, etc.), as well as manifestations of DVT and/or EP, amounting to at least 3 months.

 

 

4. Prevention of relapse of DVT, EP:
2.5 mg 2 times a day after at least 6 months of DVT or EP treatment with apixaban in a dose of 5 mg 2 times a day or other anticoagulant.

Patients with impaired renal function

 

For patients with mild to moderate renal impairment, the following recommendations are applied:

 

• there is no need to correct the dose when using Apixaban for prophylaxis of deep vein thrombosis of patients after planned hip or knee joint endoprosthetics, for treatment of DVT, for treatment of EP and prevention of deep vein thrombosis recurrence;

 

• Apixaban administration for patients with atrial fibrillation and creatinine concentration >1.5 mg/dL (133 µmol/l) in plasma, combined with age >80 years or body weight <60 kg, requires dose reduction as described above. If other criteria for dose reduction (age, body weight) are not met, no therapy correction is required.

 

For patients with severe renal impairment (with Cl creatinine 15-29 ml/min), the following recommendations are applied:

 

• Apixaban should be used with caution for prophylaxis of DVT in patients after planned hip or knee replacement, for treatment of DVT, for treatment of EP and prevention of recurrence of DVT, EP;

 

• for patients with atrial fibrillation the dose of Apixaban should be applied 2.5 mg 2 times a day. There is no data on Apixaban administration for patients with Cl creatinine <15 ml/min and for dialysis patients. In this regard, the use of Eliquis® preparation in such patients is contraindicated.

 

 

Elderly patients.

 

Correction of the dose for elderly patients is not required.

 

 

​​​​​​​

• Hypersensitivity to Apixaban or any other component of the drug;

 

• active, clinically significant bleeding;

 

• Liver diseases, accompanied by disorders in the blood-clotting system and a clinically significant risk of bleeding;

 

• diseases or conditions characterized by a significant risk of heavy bleeding: current or recent exacerbation of gastrointestinal ulcer; presence of malignant neoplasm with a high risk of bleeding; recent brain or spinal cord injury; recent surgical intervention in the brain or spinal cord, as well as in the visual organ; recent haemorrhagic stroke; established or suspected esophageal varicose veins; arteriovenous malformation; vascular aneurysm;

 

• Dysfunction of the kidneys with Cl creatinine less than 15 ml/min, as well as use for dialysis patients;

 

• under 18 years of age;

 

• pregnancy;

 

• lactation period;

 

• Simultaneous use with any other anticoagulant drugs, including non-fractionated heparin (NFH), low molecular weight heparins  (including enoxaparin, dalteparin), heparin derivatives (including fondaparinux), oral anticoagulants (including rivaroxaban, dabigatran), unless the patient is transferred to or from apixaban therapy or the unfractionated heparin is prescribed in doses necessary to maintain the permeability of the central venous or arterial catheter.

 

• congenital lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

 

 

Be careful!

 

Risk of bleeding. It is not recommended to use the drug in liver diseases accompanied by disorders in the blood coagulation system and clinically significant risk of bleeding. It is necessary to stop using the drug in case of severe bleeding.

 

Caution should be exercised when concurrently using apixaban with HDPA (including acetylsalicylic acid, as these drugs increase the risk of bleeding.

 

 

Symptoms:

 

An overdose increases the risk of bleeding. In controlled clinical trials, Apixaban was taken by orally healthy volunteers at doses of up to 50 mg/day for 3 to 7 days (25 mg 2 times a day for 7 days or 50 mg 1 time a day for 3 days); no clinically significant adverse effects were observed.

 

 

Treatment:

 

The use of activated carbon should be considered.

The antidote is unknown. The use of hemodialysis in case of Apixaban overdose is not expected to be an effective measure.

Determination of the frequency of adverse reactions: often (1/100, <1/10), not often (1/1000, <1/100), rarely (1/10 000, <1/1000).

 

 

Prevention of venous thromboembolism in patients after planned hip or knee replacement.

 

• Blood and lymphatic system: often - anemia (including postoperative and posthemorrhagic, accompanied by corresponding changes in the results of laboratory tests), bleeding (including hematoma, vaginal and urethral bleeding); not often - thrombocytopenia (including a decrease in the number of platelets).

 

• Immune system: rarely - hypersensitivity.

 

• Visual system: rarely - hemorrhage in eyeball tissue (including conjunctival hemorrhage).

 

• Cardiovascular system: rarely - arterial hypotension (including hypotension during the procedure).

 

• Respiratory system: not often - nasal bleeding; rarely - hemoptysis.

 

• Digestive system: often - nausea; not often - gastrointestinal bleeding, the presence of unchanged blood in the feces; rarely - rectal bleeding, bleeding from the gums.

 

• Liver and biliary tract: not often - increase of transaminase activity, pathological changes of liver functional samples, increase of lymphatic drainage activity in blood, increase of bilirubin concentration in blood.

 

• Musculoskeletal system: rarely - muscle hemorrhage.

 

• Urinary system: rarely - hematuria (including the corresponding changes in the results of laboratory tests).

 

• Other: often - closed trauma; not often - hemorrhage and bleeding after invasive procedures (including hematoma after the procedure, hemorrhage from the postoperative wound, hematoma in the area of the puncture of the vessel and at the site of the catheter), the presence of detachable wound, hemorrhage in the area of the incision (including hematoma in the area of the incision), bleeding during surgical intervention.

 

 

Prevention of stroke and systemic embolism of patients with atrial fibrillation

 

• Immune system: not often - hypersensitivity (including drug hypersensitivity reactions such as skin rashes, anaphylactic reactions and allergic edema).

 

• Nervous system: not often - intracranial hemorrhages, subarachnoid hemorrhages, subdural hematomas, spinal hematoma.

 

 

• Visual organ: often - hemorrhages in the eyeball tissue (including conjunctival hemorrhages).

 

• Cardiovascular system: often - other types of bleeding, hematoma; not often - abdominal bleeding.

 

• Respiratory system: often - nasal bleeding; not often - hemorrhage; rarely - bleeding into the respiratory system (including pulmonary alveolar bleeding, laryngeal and pharyngeal bleeding).

 

• Digestive system: often - gastrointestinal bleeding, rectal bleeding, bleeding from the gums; not often - hemorrhoid bleeding, presence of unchanged blood in the feces, bleeding into the mouth; rarely - retroperitoneal bleeding.

 

• Urinary system: often - hematuria.

 

• Reproductive system: not often - intermenstrual vaginal bleeding, urogenital bleeding.

 

• Reactions at the injection site: not often - bleeding at the injection site.

 

• Laboratory indicators: not often - a positive reaction in stool analysis to hidden blood.

 

• Other: often - closed injury; not often - traumatic bleeding, bleeding after the procedure, hemorrhage in the incision area.

 

 

Treatment of deep vein thrombosis, pulmonary artery thromboembolism

 

• Blood and lymphatic system: rare - haemorrhagic anemia, hemorrhagic diathesis, spontaneous hematoma.

 

• Nervous system: rarely - craniocerebral haemorrhage, hemorrhagic stroke.

 

• Visual system: not often - hemorrhage in the conjunctivus; rarely - hemorrhage in the eyeball tissue, hemorrhage in the retina, sclera, vitreous body.

 

• Hearing organs: rarely - ear hemorrhages.

 

• Cardiovascular system: often - hematomas; rarely - pericardial bleeding, other types of bleeding, bleeding into the abdominal cavity, hemorrhagic shock.

 

• Respiratory system: often - nasal bleeding; not often - haemorrhage; rarely - alveolar pulmonary bleeding.

 

• From the GIT side: often - bleeding from the gums; not often - rectal bleeding, presence of unchanged blood in the feces, hemorrhoid bleeding, gastrointestinal bleeding, bloody vomiting; rarely - melanorrhea, anal bleeding, gastric and duodenal ulcer, oral bleeding, abdominal wall haematoma, Malory Weiss syndrome, gastric bleeding, small intestine bleeding.

 

• Skin: not often - bruising, bleeding from the skin; rarely - petechiae, purple, increased susceptibility to bleeding, blood callus, bleeding from skin ulcers.

 

• Musculoskeletal system: rarely - hemorrhage in muscles.

 

• Urinary system: often - hematuria; rarely - bleeding of the urinary system.

 

• Reproductive system: often - hypermenorrhoea; not often - vaginal bleeding, metrorrhagia; rarely - menometrorrhagia, uterine bleeding, genital bleeding, hematospermia, uterine bleeding after menopause.

 

• Reactions at the injection site and other reactions: not often - hematoma at the injection site, hematoma at the vascular puncture site, bleeding from the wound, traumatic hematoma; seldom - bleeding at the injection site, hematoma at the place of infusion, periorbital hematoma, vascular pseudoaneurysm, subcutaneous hematoma, hematoma during and after the procedure, hematuria after the procedure, extrudural hematoma, subdural hematoma, kidney hematoma.

 

• Laboratory indicators: not often - the presence of blood in the urine, a positive reaction in stool testing for hidden blood; rarely - hidden blood, the presence of red blood cells in the urine.

Apixaban - 5 mg

Auxiliary substances: lactose - 100.5 mg, microcrystalline cellulose - 82 mg, sodium carmellose - 8 mg, sodium lauryl sulfate - 2 mg, magnesium stearate - 2.5 mg.

Film shell composition: opadrai II pink - 8 mg (hypromellose 15 cps - 2.96 mg, lactose monohydrate - 2.48 mg, titanium dioxide - 1.87 mg, triacetin - 0.64 mg, iron oxide dye - 0.046 mg).

You can buy Eliquis from our website absolutely legally.

 

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

 

We guarantee that you will receive your parcel with Eliquis without any problems at customs (we have our own delivery channels to countries with strict customs).

 

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

 

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

There is no prescription required!

You can legally buy Eliquis on our website without prescription!

At temperatures not exceeding 30 °C.

Keep out of the reach of children.

 

Shelf life

3 years.

Full Description on English (PDF)